摘要
目的观察茴拉西坦联合尼莫地平治疗阿尔茨海默病的疗效。方法将114例阿尔茨海默病(AD病)患者随机分为治疗组和对照组,治疗组采用茴拉西坦胶囊0.2g/次3次/天,并加用尼莫地平片20mg/次3次/d;对照组单用尼莫地平片,用法同治疗组。疗程结束后,对两组患者依照阿尔茨海默病认知功能评价量表(ADAScog)标准评估,比较两组疗效。结果治疗组总有效率85.9%,对照组总有效率66.7%,两组有效率有统计学差异(P<0.05),总体安全性良好。结论茴拉西坦联合尼莫地平治疗阿尔茨海默病的治疗效果明显,副作用小,适合临床推广应用。
Objective To observe the clinical efficacy of Aniracetam and Nimodipine in treatment of Alzheimer's disease (AD). Methods The 114 patients of alzheimer's disease (AD) were randomly divided into treatment group and control group, Treatment group using Aniracetam capsule 0. 2 g/three times/day, and combined with Nimodipine 20 mg/three times per day; The control group use Nimodipine , and the usage is the same to Treatment group. After the treatment, according to the alzheimer's disease in patients with two groups of cognitive function assessment scale (ADAS - cog) standard assessment, to compare two groups of curative effect. Results The treatment group total effectiveness 85.9%, control group total effectiveness 66.7% , two groups of efficient statistically significant (P 〈 0.05 ) , the overall safety is good. Conclusion Aniracetam and Nimodipine in treatment of Alzheimer'sdisease(AD)is obvious, small side effects, suitable for clinical application.
出处
《医药论坛杂志》
2016年第1期32-33,共2页
Journal of Medical Forum